• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 7:05:31 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email
    azta20250217_8k.htm
    false 0000933974 0000933974 2025-05-07 2025-05-07


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    PURSUANT TO SECTION 13 or 15(d) OF
    THE SECURITIES EXCHANGE ACT OF 1934
     
    Date of Report (Date of earliest event reported): May 7, 2025
     
    Azenta, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
     
    0-25434
     
    04-3040660
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission File
    Number)
     
    (IRS Employer
    Identification No.)
     
    200 Summit Drive, Burlington, MA 01803
    (Address of principal executive offices and Zip Code)
     
    (888) 229-3682
    (Registrant’s telephone number, including area code)
     
    N/A
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.01 par value
     
    AZTA
     
    The Nasdaq Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company  ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     


     

     
     
    Item 2.02 Results of Operations and Financial Condition
     
    On May 7, 2025, Azenta, Inc. (“Azenta” or the “Company”) announced via press release its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.
     
    Limitation on Incorporation by Reference. The information in Item 2.02 and Exhibit 99.1 to this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
     
    Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in this Current Report and the press release attached as an exhibit hereto, this Current Report and the press release contain forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release attached as Exhibit 99.1 hereto regarding these forward-looking statements.
     
    Item 9.01 Financial Statements and Exhibits
     
    (d) Exhibits
     
    EXHIBIT
    NUMBER
     
    DESCRIPTION
         
    99.1
      Press release issued on May 7, 2025 by Azenta, Inc
         
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    AZENTA, INC.
       
     
    /s/ Jason W. Joseph
    Date: May 7, 2025
    Jason W. Joseph
     
    Senior Vice President, General Counsel and Secretary
     
     
    Get the next $AZTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    8/6/2025$35.00Mkt Perform → Outperform
    Raymond James
    7/22/2025$35.00Equal-Weight
    Stephens
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO and Treasurer Lin Lawrence Y. bought $69,900 worth of Common (2,500 units at $27.96), increasing direct ownership by 6% to 46,013 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/12/25 4:05:13 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/4/25 4:10:05 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    11/19/24 4:10:16 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance

    BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations

    8/5/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology

    BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance the understanding of cardio-kidney-metabolic diseases and drive advancements in precision medicine for patients worldwide. The MyReason research program is an innovative initiative designed to uncover insights into the genetic mechanisms underlying kidney disease. To d

    7/31/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

    Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life SciencesProvides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registryPaves way for advances in precision kidney disease care, novel therapies, and diagnosticsBAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis effo

    7/31/25 8:30:00 AM ET
    $AZTA
    $FMS
    Industrial Machinery/Components
    Technology
    Misc Health and Biotechnology Services
    Health Care

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Azenta upgraded by Raymond James with a new price target

    Raymond James upgraded Azenta from Mkt Perform to Outperform and set a new price target of $35.00

    8/6/25 7:48:53 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Stephens resumed coverage on Azenta with a new price target

    Stephens resumed coverage of Azenta with a rating of Equal-Weight and set a new price target of $35.00

    7/22/25 7:51:21 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta upgraded by Stephens with a new price target

    Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

    12/18/24 7:25:24 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and GM, Multiomics Zhou Ginger returned $30,966 worth of Common to the company (1,085 units at $28.54), decreasing direct ownership by 4% to 26,831 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/13/25 4:47:44 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SVP and CHRO Pirogova Olga returned $30,966 worth of Common to the company (1,085 units at $28.54), decreasing direct ownership by 6% to 18,288 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/13/25 4:44:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    EVP, CFO and Treasurer Lin Lawrence Y. bought $69,900 worth of Common (2,500 units at $27.96), increasing direct ownership by 6% to 46,013 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/12/25 4:05:13 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    SEC Filings

    View All

    SEC Form 10-Q filed by Azenta Inc.

    10-Q - Azenta, Inc. (0000933974) (Filer)

    8/6/25 5:19:09 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Azenta, Inc. (0000933974) (Filer)

    8/5/25 6:50:45 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Leadership Update

    8-K - Azenta, Inc. (0000933974) (Filer)

    7/2/25 4:15:22 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    View All

    Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

    NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

    11/19/24 5:56:00 PM ET
    $AZTA
    $CON
    $ENV
    Industrial Machinery/Components
    Technology
    Medical Specialities
    Health Care

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Motor Vehicles

    AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

    Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

    9/4/24 8:00:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    SC 13G/A - Azenta, Inc. (0000933974) (Subject)

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13D/A filed by Azenta Inc.

    SC 13D/A - Azenta, Inc. (0000933974) (Subject)

    11/4/24 8:41:47 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by Azenta Inc.

    SC 13G - Azenta, Inc. (0000933974) (Subject)

    10/31/24 11:55:02 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Financials

    Live finance-specific insights

    View All

    Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance

    BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations

    8/5/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast

    BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 6, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling imp

    7/23/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

    BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

    5/7/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology